TW202334143A - 結晶咪唑并[4,5-b]吡啶化合物、醫藥組合物及彼等治療醫學症狀之用途 - Google Patents

結晶咪唑并[4,5-b]吡啶化合物、醫藥組合物及彼等治療醫學症狀之用途 Download PDF

Info

Publication number
TW202334143A
TW202334143A TW111143263A TW111143263A TW202334143A TW 202334143 A TW202334143 A TW 202334143A TW 111143263 A TW111143263 A TW 111143263A TW 111143263 A TW111143263 A TW 111143263A TW 202334143 A TW202334143 A TW 202334143A
Authority
TW
Taiwan
Prior art keywords
compound
imidazo
methoxy
methyl
benzyl
Prior art date
Application number
TW111143263A
Other languages
English (en)
Chinese (zh)
Inventor
班諾特 羅伯特
Original Assignee
美商建新公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商建新公司 filed Critical 美商建新公司
Publication of TW202334143A publication Critical patent/TW202334143A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW111143263A 2021-11-12 2022-11-11 結晶咪唑并[4,5-b]吡啶化合物、醫藥組合物及彼等治療醫學症狀之用途 TW202334143A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21207942.0 2021-11-12
EP21207942.0A EP4180428A1 (en) 2021-11-12 2021-11-12 Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Publications (1)

Publication Number Publication Date
TW202334143A true TW202334143A (zh) 2023-09-01

Family

ID=78617277

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111143263A TW202334143A (zh) 2021-11-12 2022-11-11 結晶咪唑并[4,5-b]吡啶化合物、醫藥組合物及彼等治療醫學症狀之用途

Country Status (10)

Country Link
US (3) US11814383B2 (cg-RX-API-DMAC10.html)
EP (2) EP4180428A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024543413A (cg-RX-API-DMAC10.html)
CN (1) CN118843624A (cg-RX-API-DMAC10.html)
AU (1) AU2022387516A1 (cg-RX-API-DMAC10.html)
CA (1) CA3237156A1 (cg-RX-API-DMAC10.html)
IL (1) IL312625A (cg-RX-API-DMAC10.html)
MX (1) MX2024005766A (cg-RX-API-DMAC10.html)
TW (1) TW202334143A (cg-RX-API-DMAC10.html)
WO (1) WO2023086564A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067914B1 (en) * 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
EP4180428A1 (en) 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
AU2024273547A1 (en) * 2023-05-17 2025-12-04 Centrexion Therapeutics Corporation PARTICLES OF IMIDAZO [4,5-b] PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
MA40698A3 (fr) 2014-12-18 2020-01-31 Genzyme Corp Formulations pharmaceutiques d'inhibiteurs de kinase associée à la tropomyosine (trk)
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
MX2021001957A (es) 2018-08-22 2021-07-15 Cullgen Shanghai Inc Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
BR112022016901A2 (pt) * 2020-02-26 2022-12-06 Cullgen Shanghai Inc Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso
EP4180428A1 (en) 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Also Published As

Publication number Publication date
US11814383B2 (en) 2023-11-14
US20240150352A1 (en) 2024-05-09
US12291528B2 (en) 2025-05-06
EP4180428A1 (en) 2023-05-17
JP2024543413A (ja) 2024-11-21
US20230151008A1 (en) 2023-05-18
MX2024005766A (es) 2024-07-29
US20250250274A1 (en) 2025-08-07
IL312625A (en) 2024-07-01
AU2022387516A1 (en) 2024-05-23
EP4430043A1 (en) 2024-09-18
EP4430043A4 (en) 2025-11-05
WO2023086564A1 (en) 2023-05-19
CA3237156A1 (en) 2023-05-19
CN118843624A (zh) 2024-10-25

Similar Documents

Publication Publication Date Title
JP7198820B2 (ja) 置換アゼチジンジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
JP7660604B2 (ja) 2,4,6-トリフルオロ-n-[6-(1-メチル-ピペリジン-4-カルボニル)-ピリジン-2-イル]-ベンズアミドヘミコハク酸塩の大規模調製のためのプロセスおよび中間体、ならびに2,4,6-トリフルオロ-n-[6-(1-メチル-ピペリジン-4-カルボニル)-ピリジン-2-イル]-ベンズアミド酢酸塩の調製
US12291528B2 (en) Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
US11981681B2 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
EP2371830B1 (en) Method for producing diamine derivative
CA3075705A1 (en) Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
JP2007526876A (ja) Dpp−iv阻害剤としてのヘキサヒドロピリドイソキノリン
CA3133768A1 (en) Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia
AU2014231722A1 (en) Salts, co-crystals, and polymorphs of an anxiolytic compound
WO2017093519A1 (en) Dextrorphan-derivatives with suppressed central nervous activity
US20240383892A1 (en) PARTICLES OF IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS
HK40039957A (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
HK40039957B (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
HK1162467B (en) Method for producing diamine derivative